The GLP Decision: A Science-Backed Comparison of Retatrutide, Semaglutide & Tirzepatide — and How to Choose (or Wait)

Three drugs, one decision — and the internet is either a sales pitch or a wall of jargon. The GLP Decision is the version written for the actual decision in front of you: an honest, side-by-side comparison of retatrutide, semaglutide, and tirzepatide. No book can tell you which one is yours — that's between you and your doctor. This one hands you the real trial data, organized clearly, and a framework to help you choose, or wait, without the hype. What's inside: How these drugs actually work — single-, dual-, and triple-receptor agonism, explained plainly The trial data, side by side — real figures from the named trials, with honest caveats Side effects and safety, class by class What's available today — realistic cost, insurance, and timelines The compounding reality, addressed directly — the risks, with zero how-to and zero sourcing A real decision framework — built around your urgency, risk tolerance, and access 122 pages, roughly 26,700 words, a focused 2–3 hour read. Every clinical figure checked against the primary sources. This book is educational and is not medical advice. Retatrutide is an investigational medication in Phase 3 clinical trials and is not FDA-approved. Semaglutide and tirzepatide are FDA-approved prescription medications. Nothing here is a guide to obtaining or starting any medication — those decisions belong to you and a qualified healthcare provider.